Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Arthur Staddon, MD
Pennsylvania Oncology Hematology Associates
Study Chair - Warren Chow, MD
City of Hope Medical Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Hospitals Birmingham Nhs Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre
Edgbaston, Birmingham, United Kingdom
- City of Hope
Duarte, California, United States
- Edward Cancer Center
Naperville, Illinois, United States
- University of Iowa
Iowa City, Iowa, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Pennsylvania Oncology Hematology Associates
Philadelphia, Pennsylvania, United States
- Md Anderson
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2011
- Primary completion
- 28 Feb 2018
- Completion
- 28 Feb 2018
- Last update posted
- 10 Mar 2023
- Registered enrollment
- 47
- Registry id
- NCT01330966
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.